Zheng Lejie, Smit Amelia K, Cust Anne E, Janda Monika
Centre for Health Services Research, The University of Queensland, St. Lucia, QLD 4067, Australia.
The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, NSW 2006, Australia.
J Pers Med. 2024 Aug 14;14(8):863. doi: 10.3390/jpm14080863.
This scoping review aims to systematically gather evidence from personalized cancer-screening studies across various cancers, summarize key components and outcomes, and provide implications for a future personalized melanoma-screening strategy. Peer-reviewed articles and clinical trial databases were searched for, with restrictions on language and publication date. Sixteen distinct studies were identified and included in this review. The studies' results were synthesized according to key components, including risk assessment, risk thresholds, screening pathways, and primary outcomes of interest. Studies most frequently reported about breast cancers ( = 7), followed by colorectal ( = 5), prostate ( = 2), lung ( = 1), and ovarian cancers ( = 1). The identified screening programs were evaluated predominately in Europe ( = 6) and North America ( = 4). The studies employed multiple different risk assessment tools, screening schedules, and outcome measurements, with few consistent approaches identified across the studies. The benefit-harm assessment of each proposed personalized screening program indicated that the majority were feasible and effective. The establishment of a personalized screening program is complex, but results of the reviewed studies indicate that it is feasible, can improve participation rates, and screening outcomes. While the review primarily examines screening programs for cancers other than melanoma, the insights can be used to inform the development of a personalized melanoma screening strategy.
本范围综述旨在系统地收集各类癌症个性化癌症筛查研究的证据,总结关键组成部分和结果,并为未来的个性化黑色素瘤筛查策略提供启示。检索了同行评审文章和临床试验数据库,并对语言和出版日期进行了限制。共识别出16项不同的研究并纳入本综述。根据关键组成部分对研究结果进行了综合,包括风险评估、风险阈值、筛查途径和感兴趣的主要结果。研究报告最多的是乳腺癌(n = 7),其次是结直肠癌(n = 5)、前列腺癌(n = 2)、肺癌(n = 1)和卵巢癌(n = 1)。已确定的筛查项目主要在欧洲(n = 6)和北美(n = 4)进行了评估。这些研究采用了多种不同的风险评估工具、筛查时间表和结果测量方法,研究中几乎没有发现一致的方法。对每个提议的个性化筛查项目的利弊评估表明,大多数项目是可行且有效的。建立个性化筛查项目很复杂,但综述研究的结果表明,它是可行的,可以提高参与率和筛查效果。虽然本综述主要研究黑色素瘤以外癌症的筛查项目,但这些见解可用于为个性化黑色素瘤筛查策略的制定提供参考。